We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Consensus PT $43 · 1 analysts
Stored first · Google News · Yahoo Finance (English)
Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade - dars.gov.et
Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade dars.gov.et
If You Invested $1,000 in KYNTRA BIO INC (KYNB) - Stock Titan
If You Invested $1,000 in KYNTRA BIO INC (KYNB) Stock Titan
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 - Moomoo
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 Moomoo
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 - Moomoo
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 Moomoo
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo GuruFocus
Kyntra Bio initiated with an Outperform at Oppenheimer - TipRanks
Kyntra Bio initiated with an Outperform at Oppenheimer TipRanks
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | After market close (AMC) | $-3.27 | — | — | $1.22M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.15 | — | — | $2.74M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-16.43 | — | — | $26.49M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-12.19 | — | — | $26.36M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 09. 24. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 08. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 49,511 | $335.69K | 0.00% | — | New position |